alagebrium has been researched along with pyridoxamine in 4 studies
| Studies (alagebrium) | Trials (alagebrium) | Recent Studies (post-2010) (alagebrium) | Studies (pyridoxamine) | Trials (pyridoxamine) | Recent Studies (post-2010) (pyridoxamine) |
|---|---|---|---|---|---|
| 83 | 10 | 31 | 672 | 9 | 146 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuttle, KR; Williams, ME | 1 |
| Imaizumi, T; Yamagishi, S | 1 |
| Barter, PJ; Brown, BE; Davies, MJ; Nobécourt, E; Rye, KA; Yadav, S; Zeng, J | 1 |
| Engelen, L; Schalkwijk, CG; Stehouwer, CD | 1 |
3 review(s) available for alagebrium and pyridoxamine
| Article | Year |
|---|---|
The next generation of diabetic nephropathy therapies: an update.
Topics: Animals; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Glycation End Products, Advanced; Glycosaminoglycans; Humans; Indoles; Maleimides; Models, Animal; Protein Kinase C; Pyridoxamine; Renal Agents; Thiazoles | 2005 |
[Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Topics: Animals; Clinical Trials as Topic; Depression, Chemical; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Humans; Oxidative Stress; Pyridoxamine; Thiadiazoles; Thiamine; Thiazoles; Thiazolidines | 2005 |
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enzyme Inhibitors; Evidence-Based Medicine; Female; Glycation End Products, Advanced; Guanidines; Humans; Hyperglycemia; Male; Pyridoxamine; Thiamine; Thiazoles; Treatment Outcome | 2013 |
1 other study(ies) available for alagebrium and pyridoxamine
| Article | Year |
|---|---|
Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.
Topics: Apolipoprotein A-I; Arginine; Cross-Linking Reagents; Glycosylation; Guanidines; Humans; Lipoproteins, HDL; Lysine; Metformin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyridoxamine; Pyruvaldehyde; Thiazoles; Tryptophan | 2008 |